Global CAR T-Cell Therapy Market

CAR T-Cell Therapy Market Size, Share, Growth Analysis, By Product (Yescarta, Kymriah), By Target (CD19, BCMA), By Indication (Multiple Myeloma, B-Cell Lymphoma), By Therapy Type (Monotherapy, Combination therapy), By Demographic, By Administration Type, By Region - Industry Forecast 2026-2033

Report ID: SQMIG35H2300 | Region: Global | Published Date: July, 2025
Pages: 197 |Tables: 201 |Figures: 80

To request a free sample copy of this report, please complete the form below.

Our Clients

  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt
  • Schineder Electric
  • KSIA - Korea Semiconductor Industry Association
  • Hitachi Astemo Limited
  • Samsung Electronics
  • Halvo holdings
  • NTT corporation
  • AGC Inc
  • Siemens AG
  • Unilever
  • Merck Pharmaceuticals
  • Atlas Copco
  • Hologic - Medical Technology company
  • Novartis
  • Henkel
  • Reckitt

    • FAQs

    Global CAR T-Cell Therapy Market size was valued at USD 5 Billion in 2024 and is poised to grow from USD 6.91 Billion in 2025 to USD 92 Billion by 2033, growing at a CAGR of 38.2% during the forecast period (2026–2033).

    CAR T-cell therapy companies should focus on research to improve efficacy of their offerings and make them more affordable as well. CAR T-cell therapy companies should also focus on providing CAR T-cell therapies for a wide variety of diseases to maximize their business scope in the long run. Partnerships, government grants, and mergers are some key aspects that will play a crucial role in success of any CAR T-cell therapy company going forward. 'Legend Biotech (USA)', 'Allogene Therapeutics (USA)', 'Cellectis (France)', 'Precision BioSciences (USA)', 'Arcellx (USA)', 'Autolus Therapeutics (UK)', 'Immatics N.V. (Germany)', 'Caribou Biosciences (USA)', 'Tessa Therapeutics (Singapore)', 'Sorrento Therapeutics (USA)', 'Precigen, Inc. (USA)', 'SinoCellTech (China)', 'Celyad Oncology (Belgium)', 'Instil Bio (USA)', 'Poseida Therapeutics (USA)', 'Nkarta, Inc. (USA)', 'Tmunity Therapeutics (USA)', 'Innovative Cellular Therapeutics (China)', 'Miltenyi Biotec (Germany)', 'Prescient Therapeutics (Australia)'

    Personalized medicine has exhibited immense potential in recent years and as it gains popularity among patients, it is also expected to promote the demand for CAR T-cell therapy over the coming years. The efficacy of CAR T-cell therapy can be optimized through a personalized approach and this is what will drive market growth in the future.

    Development of Allogeneic CAR T-cell Therapy: CAR T-cell therapy companies can invest in the development of allogeneic therapies to eliminate the need for patient-specific manufacturing of cells and improve accessibility and affordability of CAR T-cell therapy. This move will help CAR T-cell therapy providers expand their business scope in the long run and improve chances of success in emerging markets.

    North America leads globally, holding around 45–68% of the CAR Tcell therapy market in 2023–2024, due to robust healthcare infrastructure, substantial government and private R&D funding, and strong clinical trial ecosystems. The U.S. FDA's accelerated approvals for therapies like Kymriah, Yescarta, Breyanzi, and Breyanzi for CLL underscore this dominance. Continued government backing—e.g., nearly 50% of U.S. cancer clinics running CAR T programs—reinforces regional supremacy.

    Related Reports

    Cell Analysis Market
    Buy Now GET FREE SAMPLE
    Stem Cell Therapy Market
    Buy Now GET FREE SAMPLE
    Gene Panel Market
    Buy Now GET FREE SAMPLE
    Concierge Medicine Market
    Buy Now GET FREE SAMPLE

    Feedback From Our Clients

    Global CAR T-Cell Therapy Market

    Report ID: SQMIG35H2300

    $5,300
    BUY NOW